AIDS 2022: Dolutegravir is effective in maintaining viral suppression in children and adolescents living with HIV

Data from randomized clinical trials have led to recommending the use of dolutegravir (DTG) in children and adolescents living with HIV. However, the actual data is still scarce.

The results of a multicenter longitudinal study were presented in 24th International AIDS Conferenceevaluating the effectiveness of DTG-based regimens in maintaining short- and long-term viral suppression in this population.

Methodology

This is a retrospective study, with a review of clinical data and viral suppression rates, of HIV-positive children and adolescents aged 0-19 years treated at clinics in 6 African countries using DTG .

Viral suppression was defined as a viral load < 1000 copies/mL. Viral load tests were assessed every 6 months after the start of the GDT and the first result was used as a reference to follow the longitudinal trend of viral suppression rates.

Read also : AIDS 2022: ART, hormone therapy and metabolic aspects

Results

A total of 11,799 children and adolescents meeting the inclusion criteria were identified. The median duration of follow-up after starting DTG was 22.4 months. 22,577 viral load results were available, ranging from 6 to 60 months after participants started DTG.

For the results of the first 6 months of DTG use, the viral suppression rate was 92.1%, with no difference between genders (91.6% in women vs 92.7% in men) or between different age groups (88.9% among 0-year-olds). at 4 years old vs 94.1% for 5 to 9 year olds vs 93.5% for 10 to 14 year olds vs 90.5% for 15 to 19 year olds). The rates of viral suppression remained without significant loss over the duration of the cohort follow-up, also between sex and age.

practical message

The results of this study are further evidence of the effectiveness of DTG in the pediatric population, including when used as a starting point for treatment.

Check out more of the PEBMED Portal coverage on AIDS 2022:

See more advantages of being a user of the PEBMED portal:

See more benefits of being a user
PEBMED portal:

7 days free with Whitebook

Application made for you, doctor, designed to bring security and objectivity to your clinical decision.

Free access to the Nursebook

Access fundamental information for your daily life such as anamnesis, semiology.

Free access to forums

Space for exchanging experiences and constructive comments on topics related to medicine and health.

unlimited access

Access news, studies, updates and more content written and reviewed by experts

Test your knowledge

Answer our quizzes and study in a simple and fun way

personalized content

Receive studies, updates, new behaviors and other specialty-segmented content via email

Your evaluation is essential to allow us to continue improving the Pebmed portal

Leave a Comment